Amara Maple
BOLOGNA, ITALY – Daniele Mandrioli, the chief scientist at the renowned Ramazzini Institute Cesare Maltoni Cancer Research Center, has been dismissed from his position, sparking widespread outrage and igniting concerns about potential undue influence from the chemical industry. The ouster, first reported by investigative journalist Carey Gillam, comes as Mandrioli led a comprehensive, independently funded study into the safety of glyphosate, the active ingredient in Bayer-Monsanto’s widely used herbicide, Roundup. The incident underscores a persistent global tension between independent scientific inquiry into controversial chemicals and the powerful economic interests of the agrochemical sector.
The Ramazzini Institute and the Global Glyphosate Study
Established in 1971 near Bologna, Italy, the Ramazzini Institute has long been a pillar of toxicology research, conducting extensive animal studies on over 200 substances to inform regulatory bodies worldwide, particularly in Europe and the United States. Its work is characterized by its independence, often conducting studies without direct funding from the industries whose products it investigates. This commitment to autonomy was particularly evident in its "Global Glyphosate Study."
Launched several years ago, the ambitious multi-pronged study aimed to explore the effects of glyphosate herbicides at "current real-world levels" on various toxicological endpoints, including carcinogenicity and other health impacts. Crucially, the research was financed through "worldwide crowdfunding," deliberately eschewing chemical industry funding to maintain impartiality. This approach stood in stark contrast to many industry-funded studies, which have frequently been criticized for potential biases.
Under Dr. Mandrioli’s leadership, the study had already yielded significant preliminary findings. Last summer, the Institute issued a report that, according to Mandrioli, "strengthened evidence that glyphosate herbicides, at doses that regulators consider safe, cause tumors in these animals and could be causing cancers in humans." This followed an earlier study from the Institute indicating that glyphosate could also exert endocrine and reproductive impacts. These findings directly challenged regulatory assurances of glyphosate’s safety and drew considerable attention from the scientific community and public health advocates.
The Dismissal and Allegations of Industry Pressure
Dr. Mandrioli, who had been with the Institute for many years and was known for his outspoken stance on glyphosate, was reportedly informed of his dismissal, effective at the end of January 2026. The decision to remove him from his post has been met with incredulity and strong condemnation from other scientists associated with the Ramazzini Institute. They are openly questioning assertions by Ramazzini Institute President Loretta Masotti that the termination was not a result of pressure from the chemical industry.
Among the most vocal critics is Dr. Philip Landrigan, head of the International Scientific Advisory Committee of the Ramazzini Institute. In a January 21 letter to Masotti, Dr. Landrigan unequivocally stated, "Dr. Mandrioli has been subjected to vicious attacks by the chemical industry because the findings of the Institute’s independent research have cost these companies money and hurt their bottom line." This sentiment reflects a deep-seated concern within the scientific community that Mandrioli’s ouster is a direct consequence of his research challenging powerful corporate interests.
Further fueling the controversy is the reported lack of consultation with the Institute’s advisory board and other key academics involved in the research before Mandrioli’s dismissal. This perceived lack of due process has led many to argue that the decision not only undermines Mandrioli’s integrity but also threatens the very independence and scientific credibility of the Ramazzini Institute itself. Letters and petitions are reportedly circulating, attempting to reverse the decision and safeguard the institution’s autonomy.
A Pattern of Attacks on Independent Scientists
The allegations surrounding Dr. Mandrioli’s dismissal are not isolated incidents but rather fit into a broader pattern of what critics describe as systematic attacks by the chemical industry on scientists and institutions that publish findings critical of glyphosate. Carey Gillam, a veteran investigative journalist and author of "Whitewash: The Story of a Weed Killer, Cancer, and the Corruption of Science" and "The Monsanto Papers: Deadly Secrets, Corporate Corruption, and One Man’s Search for Justice," has extensively documented this phenomenon. Gillam, who currently leads "The New Lede," the journalism initiative of the Environmental Working Group, highlighted in an interview with Corporate Crime Reporter that the tactics employed against Mandrioli mirror those previously used against other scientific bodies.
A prominent example cited by Gillam is the International Agency for Research on Cancer (IARC), an arm of the World Health Organization. In 2015, IARC classified glyphosate as "probably carcinogenic to humans" (Group 2A), a classification based on "limited evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals." This finding, reached by an independent panel of international experts, sent shockwaves through the agrochemical industry.
Following IARC’s classification, industry players, including Monsanto (now owned by Bayer), launched an aggressive campaign to discredit the agency and its scientists. This campaign involved accusations of publishing "junk science," manipulating results, and intentionally misleading findings. Scientists faced personal attacks on their integrity and credibility, subpoenas demanding personal emails, and intense pressure on the World Health Organization to retract the IARC findings. The industry also lobbied for a Congressional investigation into IARC and sought to strip its funding, leading to a "very big deal" that "left a tarnish on IARC because of its glyphosate work," according to Gillam. Similar attacks have been launched against independent scientists at institutions like the University of Washington who have studied glyphosate’s health effects.
The Avalanche of Litigation: Glyphosate and Non-Hodgkin Lymphoma
The IARC classification in 2015 served as a critical catalyst for an "avalanche of litigation" in the United States. Thousands of individuals diagnosed with non-Hodgkin lymphoma, who claimed their disease was caused by exposure to glyphosate-based herbicides like Roundup, filed lawsuits against Monsanto. The sheer volume of these cases is staggering, with close to 200,000 lawsuits initially filed.
In 2018, just as the very first trials were commencing, the German pharmaceutical and life sciences giant Bayer acquired Monsanto for approximately $63 billion. This acquisition, intended to create an agricultural powerhouse, almost immediately burdened Bayer with immense legal liabilities. To date, Bayer has paid out over $11 billion in settlements and jury verdicts related to the Roundup litigation. Despite these massive payouts, Bayer reports that approximately 50,000 to 60,000 cases remain outstanding from the initial wave of lawsuits.
The litigation has seen a mix of outcomes, with dozens of cases reaching jury verdicts. While Bayer has won several trials, plaintiffs have also secured significant victories, often resulting in exceptionally large awards. Notable early verdicts include a $289 million award in 2018, followed by a $2 billion verdict, and another individual receiving $80 million. These high-profile verdicts, alongside a scattering of smaller ones, have underscored the financial risk to Bayer and kept the pressure on for settlements. Many cases have also settled on the eve of trial or shortly after they began.
Settlement amounts vary widely, with many plaintiffs receiving modest sums ($50,000 to $100,000), while others, particularly those who achieve favorable jury verdicts or strong individual settlements, have received several million dollars. The confidential nature of most settlements, however, makes a precise breakdown challenging.
The litigation has been spearheaded by several prominent plaintiffs’ firms, including The Miller Firm in Virginia, with Robin Greenwald of Weitz Luxenburg and Aimee Wagstaff of the Wagstaff law firm playing key roles. Brent Wisner, a California attorney, gained significant recognition after being brought in at the last minute to help try the very first Roundup case, a story that is now reportedly being adapted into a Netflix movie, highlighting the global impact of the litigation.
Bayer’s Legal and Legislative Strategies: The Supreme Court and "Immunity Shields"
Bayer is actively pursuing multiple strategies to put an end to the ongoing litigation and mitigate future liabilities. One significant move is its successful appeal to the U.S. Supreme Court regarding the Roundup litigation. Bayer’s central argument is based on the concept of federal pre-emption. The company contends that state-based "failure to warn" claims should not be allowed against Bayer or similarly situated companies because these claims are pre-empted by federal law.
Bayer asserts that the Environmental Protection Agency (EPA) is the chief regulator over pesticides in the U.S. Since the EPA, after its own reviews, does not currently require a cancer warning label on glyphosate products, Bayer argues that no one should be able to sue the company for failing to warn of a cancer risk. This crucial legal question is scheduled to be presented to the U.S. Supreme Court in the spring, with a decision expected by June. Bayer has expressed considerable optimism to its investors that a favorable ruling could significantly block future litigation and potentially halt current cases, offering a potential lifeline from the immense financial drain.
Beyond the courts, Bayer has also engaged in aggressive lobbying efforts to embed this pre-emption argument into federal and state law, effectively creating what critics term "immunity shields" for pesticide manufacturers. Gillam reports that Bayer has formed a coalition called the "Modern Ag Alliance," which brings together dozens of agricultural groups. This alliance lobbies lawmakers, arguing that without such legal protections, glyphosate and other essential agricultural chemicals could be in jeopardy due to the crippling costs of litigation. They frame plaintiffs’ attorneys as exploiting cancer sufferers with claims lacking scientific validity, necessitating protection for companies from "predatory law firms."
These lobbying efforts have seen some success, with "immunity shield" provisions already passed in two states and similar legislation being pursued in others. The core of these laws is that the EPA is the ultimate authority, thus precluding state-level "failure to warn" claims. Legal experts contend that the "failure to warn" claim is the "linchpin" of these lawsuits, underpinning other claims like design defect, negligence, and breach of warranty. Removing this foundational claim could severely weaken or nullify future litigation. Industry proponents are also anticipating the inclusion of some form of this language in the upcoming federal farm bill, a major piece of agricultural legislation.
The "Make America Healthy Again" Movement’s Frustration
In opposition to the industry’s legislative pushes, movements like "Make America Healthy Again" (MAHA) have emerged. Gillam highlighted MAHA’s role in successfully stripping an "immunity provision" out of a recent Congressional appropriations bill. However, MAHA activists have expressed deep frustration with the perceived lack of substantial change regarding pesticides and environmental chemicals, even under administrations they hoped would be more responsive.
They criticize the EPA for consistently prioritizing corporate interests over public health concerns. A particular point of contention arose when Bobby Kennedy, a prominent figure in the environmental movement, was appointed to a role related to the Department of Health and Human Services. An initial draft MAHA report last spring reportedly named glyphosate and atrazine as dangerous and called for more rigorous regulation. However, after significant lobbying by agrichemical companies on Capitol Hill, the final report released in the fall made no mention of these pesticides.
This perceived capitulation has led to increased activism, including petitions for the ouster of EPA officials, reflecting a deep disillusionment among environmental and health advocates who feel their concerns are being sidelined.
Implications for Scientific Independence and Public Trust
The dismissal of Dr. Daniele Mandrioli from the Ramazzini Institute represents more than just a personnel change; it is a critical incident that reverberates through the scientific community and public discourse. It highlights the immense pressures faced by independent researchers investigating substances with significant economic implications. The incident raises profound questions about the sanctity of scientific independence, the integrity of research institutions, and the capacity of regulatory bodies to resist corporate influence.
If institutions like the Ramazzini Institute, known for their rigorous, independent toxicology studies, can be pressured to remove leading scientists due to their findings, it sends a chilling message to others. Such actions risk deterring critical research, eroding public trust in scientific findings, and ultimately compromising public health protections. The ongoing battles in courtrooms and legislative halls further underscore the complex interplay between science, law, politics, and industry, with the ultimate implications for public health and environmental safety yet to be fully determined. The outcome of the Supreme Court’s decision on pre-emption and the ongoing legislative efforts will significantly shape the future landscape of pesticide regulation and accountability in the United States and potentially beyond.
Nila Kartika Wati
Jia Lissa
Ana Megawati
Pevita Pearce
Joko Widodo
admin